Foghorn Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Foghorn Therapeutics

04/08/2025 13:36

Foghorn Therapeutics Inc FHTX.OQ FHTX.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

The Cambridge Massachusetts-based  company is expected to report a 5.7% decrease in revenue to $6.498 million from $6.89 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Foghorn Therapeutics Inc is for a loss of 36 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $11.50, about 56.6% above its last closing price of $4.99

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.33
-0.34
-0.30
Beat
12.3
Dec. 31 2025
-0.27
-0.33
-0.30
Beat
8.3
Sep. 30 2024
-0.42
-0.44
-0.31
Beat
29.6​
Jun. 30 2024
-0.63
-0.65
-0.45
Beat
31.3
​​Mar. 31 2024
-0.56
-0.63
-0.59
Beat
6.9
Dec. 31 2023
-0.94
-0.76
-0.57
Beat
25.3​
Sep. 30 2023
-0.74
-0.75
-0.34
Beat
54.7
Jun. 30 2023
-0.74
-0.73
-0.70
Beat
4.8

This summary was machine generated August 4 at 12:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)